Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria

Human Immunology

Volumn 77, Issue 4, 2016, Pages 346-352

  Redfield, Robert R ^a   Ellis, Thomas M ^a   Zhong, Weixiong ^a   Scalea, Joseph R ^a   Zens, Tiffany J ^a   Mandelbrot, Didier ^a   Muth, Brenda L ^a   Panzer, Sarah ^a   Samaniego, Millie ^b   Kaufman, Dixon B ^a   Astor, Brad C ^a   Djamali, Arjang ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Chronic Allograft Rejection; Outcomes; Renal transplantation

Indexed keywords

COMPLEMENT COMPONENT C4D; DEXAMETHASONE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; ALLOANTIBODY;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CHRONIC ACTIVE ANTIBODY MEDIATED REJECTION; CHRONIC GRAFT REJECTION; CHRONICITY; FEMALE; FOLLOW UP; GLOMERULOPATHY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOPSY; GRAFT REJECTION; IMMUNOLOGY; OUTCOME ASSESSMENT; PATHOLOGY;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BIOPSY; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PATIENT OUTCOME ASSESSMENT;

EID: 84962362104     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2016.01.018     Document Type: Article

References (32)

1. Loupy A., Hill G.S., Jordan S.C. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat. Rev. Nephrol. 2012, 8:348.
2. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., Chapman J.R. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 2003, 349:2326.
3. Li C., Yang C.W. The pathogenesis and treatment of chronic allograft nephropathy. Nat. Rev. Nephrol. 2009, 5:513.
4. Djamali A., Kaufman D.B., Ellis T.M., Zhong W., Matas A., Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am. J. Transplant. 2014, 14:255.
5. Sellares J., de Freitas D.G., Mengel M., Reeve J., Einecke G., Sis B., et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am. J. Transplant. 2012, 12:388.
6. Loupy A., Lefaucheur C., Vernerey D., Prugger C., Duong van Huyen J.P., Mooney N., et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med. 2013, 369:1215.
7. Aita K., Yamaguchi Y., Shimizu T., Horita S., Furusawa M., Tanabe K., et al. Histological analysis of late renal allografts of antidonor antibody positive patients with C4d deposits in peritubular capillaries. Clin. Transplant. 2004, 18(Suppl. 11):7.
8. Mauiyyedi S., Pelle P.D., Saidman S., Collins A.B., Pascual M., Tolkoff-Rubin N.E., et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 2001, 12:574.
9. Smith R.N., Malik F., Goes N., Farris A.B., Zorn E., Saidman S., et al. Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl. Immunol. 2012, 27:107.
10. Haas M., Sis B., Racusen L.C., Solez K., Glotz D., Colvin R.B., et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 2014, 14:272.
11. Brokhof M.M., Sollinger H.W., Hager D.R., Muth B.L., Pirsch J.D., Fernandez L.A., et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation 2014, 97:612.
12. Djamali A., Muth B.L., Ellis T.M., Mohamed M., Fernandez L.A., Miller K.M., et al. Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney Int. 2013, 83:1185.
13. de Kort H., Willicombe M., Brookes P., Dominy K.M., Santos-Nunez E., Galliford J.W., et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am. J. Transplant. 2013, 13:485.
14. Sis B., Jhangri G.S., Riopel J., Chang J., de Freitas D.G., Hidalgo L., et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am. J. Transplant. 2012, 12:1168.
15. Loupy A., Hill G.S., Suberbielle C., Charron D., Anglicheau D., Zuber J., et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am. J. Transplant. 2011, 11:56.
16. Tait B.D., Susal C., Gebel H.M., Nickerson P.W., Zachary A.A., Claas F.H., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013, 95:19.
17. Stegall M.D., Gloor J., Winters J.L., Moore S.B., Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant. 2006, 6:346.
18. Lefaucheur C., Nochy D., Andrade J., Verine J., Gautreau C., Charron D., et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am. J. Transplant. 2009, 9:1099.
19. Billing H., Rieger S., Ovens J., Susal C., Melk A., Waldherr R., et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008, 86:1214.
20. Billing H., Rieger S., Susal C., Waldherr R., Opelz G., Wuhl E., et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl. Int. 2012, 25:1165.
21. Cosio F.G., Gloor J.M., Sethi S., Stegall M.D. Transplant glomerulopathy. Am. J. Transplant. 2008, 8:492.
22. Issa N., Cosio F.G., Gloor J.M., Sethi S., Dean P.G., Moore S.B., et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008, 86:681.
23. Sijpkens Y.W., Joosten S.A., Wong M.C., Dekker F.W., Benediktsson H., Bajema I.M., et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int. 2004, 65:2409.
24. Yamanaga S., Watarai Y., Yamamoto T., Tsujita M., Hiramitsu T., Nanmoku K., et al. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches. Hum. Immunol. 2013, 74:1111.
25. Gloor J.M., Cosio F.G., Rea D.J., Wadei H.M., Winters J.L., Moore S.B., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am. J. Transplant. 2006, 6:1841.
26. Djamali A., Muth B.L., Torrealba J., Bloom D., Miller K.M., Lorentzen D., et al. Bortezomib as a rescue therapy for hyperacute and multi-drug resistant mixed acute rejection after kidney transplantation. Clin. Transpl. 2009, 485.
27. Tyden G., Ekberg H., Tufveson G., Mjornstedt L. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation 2012, 94:e21.
28. Walsh R.C., Brailey P., Girnita A., Alloway R.R., Shields A.R., Wall G.E., et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011, 91:1218.
29. Walsh R.C., Everly J.J., Brailey P., Rike A.H., Arend L.J., Mogilishetty G., et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010, 89:277.
30. Hong Y.A., Kim H.G., Choi S.R., Sun I.O., Park H.S., Chung B.H., et al. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. Transplant. Proc. 2012, 44:182.
31. Kohei N., Hirai T., Omoto K., Ishida H., Tanabe K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am. J. Transplant. 2012, 12:469.
32. Everly M.J., Rebellato L.M., Haisch C.E., Ozawa M., Parker K., Briley K.P., et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013, 95:410.